Profitability Metrics

Gross Margin
31.24%
Operating Margin
15.31%
Net Margin
15.86%

Efficiency Metrics

Revenue per Expense Ratio
1.18
R&D as % of Revenue
5.12%

Earnings Quality

EBITDA Margin
32.78%
Income Tax Rate
22.75%
EPS
25.7200000000

Balance Sheet Analysis

Current Ratio
2.20
Cash Ratio
0.33
Working Capital
$27.95B
Debt to Equity
3.57
Debt to Assets
61.47%
Equity Ratio
17.23%

Cash Flow Analysis

Operating Cash Flow Ratio
0.93%
Free Cash Flow Ratio
-0.40%
CapEx to Revenue
1.33%
Dividends Paid
$971.00M
Stock Buybacks
$2.48B
Total Shareholder Returns
$3.45B
Cash Position Change
-44.80%

Key Takeaways (2024 FY)

  • Revenue declined by 26.890660220182%, indicating potential market challenges
  • Increased dividend payments by 19.08%
  • Increased R&D investment by 5.19%

Detailed Growth Metrics

Core Performance

Revenue
-26.89%
Net Income
-30.16%
EPS
-26.07%
Operating Income
-55.32%

Operational Efficiency

R&D Expenses
5.19%
SG&A Expenses
25.16%
Operating Cash Flow
7.47%
Free Cash Flow
84.20%

Balance Sheet Health

Assets
3.11%
Debt
-78.75%
Book Value per Share
10.90%
Inventory
-11.78%

Shareholder Returns

Dividends per Share
19.08%
Shares Outstanding
-5.54%

Long Term Trends

3Y Revenue/Share
17.43%
5Y Revenue/Share
33.74%
3Y Dividend/Share
74.23%
5Y Dividend/Share
95.18%